Tonix Pharmaceuticals Holding Corp. Company Profile (NASDAQ:TNXP)

About Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP)

Tonix Pharmaceuticals Holding Corp. logoTonix Pharmaceuticals Holding Corp., a clinical-stage pharmaceutical company, engages in developing pharmaceutical products for central nervous system disorders. The company’s lead program focuses on post-traumatic stress disorder (PTSD) that is characterized by chronic disability, inadequate treatment options, high utilization of healthcare services, and economic burden. Its lead product candidate includes TNX-102 SL, a cyclobenzaprine HCl sublingual tablet, which is in Phase III clinical stage for the treatment of PTSD; and Phase III clinical stage for the treatment of military-related PTSD. The company’s product candidates also include TNX-601, an oral formulation of tianeptine oxalate for PTSD and cognitive dysfunction associated with steroid use; TNX-801, a smallpox-preventing vaccine based on a live synthetic version of horsepox virus; TNX-301, a fixed-dose combination drug product for alcohol use disorders; and TNX-701 for radiation injuries. Tonix Pharmaceuticals Holding Corp. was founded in 2007 and is based in New York, New York.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drug Manufacturers - Major
  • Sub-Industry: N/A
  • Symbol: NASDAQ:TNXP
  • CUSIP: N/A
  • Web: www.tonixpharma.com
Capitalization:
  • Market Cap: $31.16 million
  • Outstanding Shares: 7,508,000
Average Prices:
  • 50 Day Moving Avg: $3.66
  • 200 Day Moving Avg: $3.84
  • 52 Week Range: $0.33 - $9.40
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -1.80
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: N/A
  • Price / Sales: N/A
  • Book Value: $4.53 per share
  • Price / Book: 0.92
Profitability:
  • EBIDTA: ($24,360,000.00)
  • Return on Equity: -84.89%
  • Return on Assets: -78.71%
Debt:
  • Current Ratio: 19.39%
  • Quick Ratio: 19.39%
Misc:
  • Average Volume: 112,373 shs.
  • Beta: 2.86
  • Short Ratio: 7.49
 

Frequently Asked Questions for Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP)

What is Tonix Pharmaceuticals Holding Corp.'s stock symbol?

Tonix Pharmaceuticals Holding Corp. trades on the NASDAQ under the ticker symbol "TNXP."

How were Tonix Pharmaceuticals Holding Corp.'s earnings last quarter?

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) posted its quarterly earnings data on Monday, August, 14th. The company reported ($0.65) EPS for the quarter, topping the Zacks' consensus estimate of ($0.78) by $0.13. View Tonix Pharmaceuticals Holding Corp.'s Earnings History.

When will Tonix Pharmaceuticals Holding Corp. make its next earnings announcement?

Tonix Pharmaceuticals Holding Corp. is scheduled to release their next quarterly earnings announcement on Wednesday, November, 8th 2017. View Earnings Estimates for Tonix Pharmaceuticals Holding Corp..

Where is Tonix Pharmaceuticals Holding Corp.'s stock going? Where will Tonix Pharmaceuticals Holding Corp.'s stock price be in 2017?

5 analysts have issued 1-year target prices for Tonix Pharmaceuticals Holding Corp.'s shares. Their forecasts range from $6.00 to $10.00. On average, they expect Tonix Pharmaceuticals Holding Corp.'s share price to reach $8.33 in the next year. View Analyst Ratings for Tonix Pharmaceuticals Holding Corp..

Who are some of Tonix Pharmaceuticals Holding Corp.'s key competitors?

Who owns Tonix Pharmaceuticals Holding Corp. stock?

Tonix Pharmaceuticals Holding Corp.'s stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include B. Riley Financial Inc. (5.05%), Vanguard Group Inc. (2.46%), Susquehanna International Group LLP (1.20%) and Kingdon Capital Management L.L.C. (0.86%). Company insiders that own Tonix Pharmaceuticals Holding Corp. stock include Bradley Saenger, Bruce Daugherty, Ernest Mario, Gregory M Sullivan, John B Rhodes and Seth Lederman. View Institutional Ownership Trends for Tonix Pharmaceuticals Holding Corp..

Who sold Tonix Pharmaceuticals Holding Corp. stock? Who is selling Tonix Pharmaceuticals Holding Corp. stock?

Tonix Pharmaceuticals Holding Corp.'s stock was sold by a variety of institutional investors in the last quarter, including Susquehanna International Group LLP and Kingdon Capital Management L.L.C.. View Insider Buying and Selling for Tonix Pharmaceuticals Holding Corp..

Who bought Tonix Pharmaceuticals Holding Corp. stock? Who is buying Tonix Pharmaceuticals Holding Corp. stock?

Tonix Pharmaceuticals Holding Corp.'s stock was purchased by a variety of institutional investors in the last quarter, including B. Riley Financial Inc. and Vanguard Group Inc.. Company insiders that have bought Tonix Pharmaceuticals Holding Corp. stock in the last two years include Bradley Saenger, Bruce Daugherty, Ernest Mario, Gregory M Sullivan, John B Rhodes and Seth Lederman. View Insider Buying and Selling for Tonix Pharmaceuticals Holding Corp..

How do I buy Tonix Pharmaceuticals Holding Corp. stock?

Shares of Tonix Pharmaceuticals Holding Corp. can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Tonix Pharmaceuticals Holding Corp.'s stock price today?

One share of Tonix Pharmaceuticals Holding Corp. stock can currently be purchased for approximately $4.15.


MarketBeat Community Rating for Tonix Pharmaceuticals Holding Corp. (NASDAQ TNXP)
Community Ranking:  3.5 out of 5 (star star star half star)
Outperform Votes:  109 (Vote Outperform)
Underperform Votes:  46 (Vote Underperform)
Total Votes:  155
MarketBeat's community ratings are surveys of what our community members think about Tonix Pharmaceuticals Holding Corp. and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Hold Rating, 4 Buy Ratings
Consensus Rating:Buy (Score: 2.80)
Consensus Price Target: $8.33 (100.80% upside)

Analysts' Ratings History for Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
8/23/2017Dawson JamesReiterated RatingBuy$9.00MediumView Rating Details
8/22/2017Drexel HamiltonInitiated CoverageBuyHighView Rating Details
8/18/2017Roth CapitalUpgradeNeutral -> Buy$6.00HighView Rating Details
6/26/2017AegisInitiated CoverageBuy$10.00HighView Rating Details
12/20/2016Oppenheimer Holdings, Inc.Reiterated RatingHoldN/AView Rating Details
9/7/2016Cantor FitzgeraldDowngradeBuy -> HoldN/AView Rating Details
(Data available from 9/25/2015 forward)

Earnings

Earnings History for Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP)
Earnings by Quarter for Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP)
Earnings History by Quarter for Tonix Pharmaceuticals Holding Corp. (NASDAQ TNXP)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/8/2017($0.69)N/AView Earnings Details
8/14/2017Q2 2017($0.78)($0.65)ViewN/AView Earnings Details
5/15/2017Q1 2017($1.36)($1.27)ViewN/AView Earnings Details
11/10/2016Q3 2016($0.34)($0.29)ViewN/AView Earnings Details
5/9/2016Q1($0.63)($0.74)ViewN/AView Earnings Details
3/4/2016Q4($0.66)($0.71)ViewN/AView Earnings Details
8/10/2015Q215($0.65)($0.73)ViewN/AView Earnings Details
5/11/2015Q115($0.54)($0.71)ViewN/AView Earnings Details
3/3/2015Q414($0.81)($0.83)ViewN/AView Earnings Details
11/10/2014Q314($0.69)($0.71)ViewN/AView Earnings Details
8/8/2014Q214($0.53)($0.61)ViewN/AView Earnings Details
5/13/2014Q114($0.35)($0.59)ViewN/AView Earnings Details
3/31/2014($0.46)($0.74)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP)
2017 EPS Consensus Estimate: ($2.79)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.83)($0.83)($0.83)
Q2 20171($0.69)($0.69)($0.69)
Q3 20171($0.65)($0.65)($0.65)
Q4 20171($0.62)($0.62)($0.62)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP)
Insider Ownership Percentage: 4.00%
Institutional Ownership Percentage: 28.27%
Insider Trades by Quarter for Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP)
Institutional Ownership by Quarter for Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP)
Insider Trades by Quarter for Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/17/2017Seth LedermanCEOBuy20,000$3.00$60,000.00View SEC Filing  
6/30/2017Ernest MarioDirectorSell6,105$4.28$26,129.40View SEC Filing  
6/30/2017Seth LedermanCEOBuy5,000$4.33$21,650.00View SEC Filing  
6/26/2017Seth LedermanCEOBuy5,000$4.40$22,000.00View SEC Filing  
6/20/2017Seth LedermanCEOBuy20,000$4.22$84,400.00View SEC Filing  
11/23/2016Ernest MarioDirectorBuy120,000$0.41$49,200.00View SEC Filing  
9/13/2016Ernest MarioDirectorBuy100,000$0.79$79,000.00View SEC Filing  
6/22/2016Seth LedermanCEOBuy20,000$2.08$41,600.00View SEC Filing  
6/21/2016Bradley SaengerCFOBuy2,000$2.00$4,000.00View SEC Filing  
6/21/2016Bruce DaughertyInsiderBuy100,000$2.00$200,000.00View SEC Filing  
6/21/2016John B RhodesDirectorBuy25,000$2.00$50,000.00View SEC Filing  
6/3/2016Gregory M SullivanInsiderBuy20,000$2.50$50,000.00View SEC Filing  
5/12/2016Ernest MarioDirectorBuy31,042$2.30$71,396.60View SEC Filing  
5/11/2016Ernest MarioDirectorBuy8,210$2.24$18,390.40View SEC Filing  
3/23/2016Seth LedermanCEOBuy8,000$2.44$19,520.00View SEC Filing  
3/16/2016Ernest MarioDirectorBuy75,000$2.29$171,750.00View SEC Filing  
9/30/2015Gregory M SullivanInsiderBuy5,000$5.18$25,900.00View SEC Filing  
9/28/2015Gregory M SullivanInsiderBuy4,694$5.95$27,929.30View SEC Filing  
9/25/2015Seth LedermanCEOBuy6,000$6.50$39,000.00View SEC Filing  
8/26/2015Ernest MarioDirectorBuy10,000$6.05$60,500.00View SEC Filing  
8/25/2015Ernest MarioDirectorBuy1,468$6.40$9,395.20View SEC Filing  
8/24/2015Ernest MarioDirectorBuy2,532$6.20$15,698.40View SEC Filing  
8/20/2015Ernest MarioDirectorBuy6,000$6.64$39,840.00View SEC Filing  
8/17/2015Ernest MarioDirectorBuy15,000$6.93$103,950.00View SEC Filing  
7/17/2015John B RhodesDirectorBuy6,000$7.50$45,000.00View SEC Filing  
7/17/2015Leland GershellCFOBuy1,000$7.50$7,500.00View SEC Filing  
6/11/2015Gregory M SullivanInsiderBuy4,500$8.38$37,710.00View SEC Filing  
3/17/2015Seth LedermanCEOBuy2,000$7.02$14,040.00View SEC Filing  
3/13/2015Seth LedermanCEOBuy2,000$7.24$14,480.00View SEC Filing  
3/11/2015Seth LedermanCEOBuy2,000$6.95$13,900.00View SEC Filing  
3/10/2015Charles E Iv MatherDirectorBuy1,000$6.80$6,800.00View SEC Filing  
3/9/2015Seth LedermanCEOBuy2,000$6.48$12,960.00View SEC Filing  
3/6/2015Ernest MarioDirectorBuy4,000$6.57$26,280.00View SEC Filing  
3/5/2015Seth LedermanCEOBuy2,000$6.27$12,540.00View SEC Filing  
2/9/2015Ernest MarioDirectorBuy30,000$5.85$175,500.00View SEC Filing  
2/9/2015Leland GershellCFOBuy5,000$5.85$29,250.00View SEC Filing  
9/27/2013Charles E Iv MatherDirectorBuy1,000$3.65$3,650.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP)
Latest Headlines for Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP)
Source:
DateHeadline
americanbankingnews.com logoTonix Pharmaceuticals Holding Corp. (TNXP) Receives Average Recommendation of "Buy" from Analysts
www.americanbankingnews.com - September 17 at 10:58 AM
seekingalpha.com logoTonix Pharmaceuticals (TNXP) Presents At Rodman & Renshaw 19th Annual Global Investment Conference - Slideshow
seekingalpha.com - September 15 at 10:04 AM
globenewswire.com logoTonix Pharmaceuticals Elects Margaret Smith Bell to the Board of Directors - GlobeNewswire (press release)
globenewswire.com - September 14 at 11:26 AM
streetinsider.com logoTonix Pharma (TNXP) Appoints Margaret Bell to Board - StreetInsider.com
www.streetinsider.com - September 14 at 11:26 AM
finance.yahoo.com logoTonix Pharmaceuticals Elects Margaret Smith Bell to the Board of Directors
finance.yahoo.com - September 14 at 11:26 AM
americanbankingnews.com logo Brokerages Anticipate Tonix Pharmaceuticals Holding Corp. (TNXP) Will Post Earnings of -$0.68 Per Share
www.americanbankingnews.com - September 13 at 4:24 AM
americanbankingnews.com logoTonix Pharmaceuticals Holding Corp. (TNXP) vs. Innovus Pharmaceuticals (INNV) Head-To-Head Comparison
www.americanbankingnews.com - September 11 at 10:06 PM
finance.yahoo.com logoCorporate News Blog - Eli Lilly's Galcanezumab Treatment Shows Positive Safety Results in the 12-Month Phase-3 Study
finance.yahoo.com - September 11 at 7:49 AM
americanbankingnews.com logoCritical Review: Tonix Pharmaceuticals Holding Corp. (TNXP) vs. Innovus Pharmaceuticals (INNV)
www.americanbankingnews.com - September 11 at 6:20 AM
americanbankingnews.com logoContrasting Tonix Pharmaceuticals Holding Corp. (TNXP) & Innovus Pharmaceuticals (INNV)
www.americanbankingnews.com - September 9 at 8:12 PM
americanbankingnews.com logoTonix Pharmaceuticals Holding Corp. (TNXP) & Innovus Pharmaceuticals (INNV) Critical Analysis
www.americanbankingnews.com - September 9 at 11:06 AM
globenewswire.com logoTonix Pharmaceuticals to Present at the Rodman & Renshaw 19th Annual Global Investment Conference - GlobeNewswire (press release)
globenewswire.com - September 6 at 9:15 AM
finance.yahoo.com logoTonix Pharmaceuticals to Present at the Rodman & Renshaw 19th Annual Global Investment Conference
finance.yahoo.com - September 6 at 9:15 AM
americanbankingnews.com logoHead to Head Contrast: Innovus Pharmaceuticals (INNV) & Tonix Pharmaceuticals Holding Corp. (TNXP)
www.americanbankingnews.com - September 5 at 6:16 AM
americanbankingnews.com logoComparing Innovus Pharmaceuticals (INNV) & Tonix Pharmaceuticals Holding Corp. (TNXP)
www.americanbankingnews.com - September 4 at 12:34 PM
americanbankingnews.com logoHead to Head Contrast: Innovus Pharmaceuticals (INNV) vs. Tonix Pharmaceuticals Holding Corp. (TNXP)
www.americanbankingnews.com - September 3 at 4:26 PM
americanbankingnews.com logoTonix Pharmaceuticals Holding Corp. (TNXP) Rating Increased to Sell at ValuEngine
www.americanbankingnews.com - September 2 at 11:52 AM
americanbankingnews.com logoFinancial Survey: Tonix Pharmaceuticals Holding Corp. (TNXP) vs. Innovus Pharmaceuticals (INNV)
www.americanbankingnews.com - August 31 at 10:31 PM
streetinsider.com logoTonix Pharma (TNXP) Released Additional Phase 2 Clinical Results in Military-Related PTSD and Design of Ongoing ... - StreetInsider.com
www.streetinsider.com - August 30 at 10:21 AM
streetinsider.com logoTonix Pharma (TNXP) Released Additional Phase 2 Clinical Results in Military-Related PTSD and Design of Ongoing ... - StreetInsider.com
www.streetinsider.com - August 30 at 10:21 AM
finance.yahoo.com logoTonix Pharmaceuticals Presented Additional Phase 2 Clinical Results in Military-Related PTSD and Design of Ongoing Phase 3 Trial at the 2017 Military Health System Research Symposium
finance.yahoo.com - August 30 at 10:21 AM
finance.yahoo.com logoTonix Pharmaceuticals Presented Additional Phase 2 Clinical Results in Military-Related PTSD and Design of Ongoing Phase 3 Trial at the 2017 Military Health System Research Symposium
finance.yahoo.com - August 30 at 10:21 AM
americanbankingnews.com logoCritical Comparison: Tonix Pharmaceuticals Holding Corp. (TNXP) versus Innovus Pharmaceuticals (INNV)
www.americanbankingnews.com - August 26 at 12:22 AM
americanbankingnews.com logo Analysts Anticipate Tonix Pharmaceuticals Holding Corp. (TNXP) to Announce -$0.68 EPS
www.americanbankingnews.com - August 25 at 8:18 PM
americanbankingnews.com logoTonix Pharmaceuticals Holding Corp. (TNXP) versus Innovus Pharmaceuticals (INNV) Critical Survey
www.americanbankingnews.com - August 23 at 8:26 PM
americanbankingnews.com logoTonix Pharmaceuticals Holding Corp. (TNXP) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - August 23 at 1:08 PM
streetinsider.com logoTonix Pharma (TNXP) to Announce Phase 2 Clinical Results & Design of Ongoing Phase 3 Trial in Military-Related PTSD
www.streetinsider.com - August 23 at 12:45 PM
americanbankingnews.com logoTonix Pharmaceuticals Holding Corp. (TNXP) Rating Reiterated by Dawson James
www.americanbankingnews.com - August 23 at 11:10 AM
americanbankingnews.com logoTonix Pharmaceuticals Holding Corp. (TNXP) Now Covered by Drexel Hamilton
www.americanbankingnews.com - August 22 at 11:58 AM
globenewswire.com logoTonix Pharmaceuticals to Present Additional Phase 2 Clinical Results and Design of Ongoing Phase 3 Trial in Military ... - GlobeNewswire (press release)
globenewswire.com - August 22 at 7:13 AM
americanbankingnews.com logoTonix Pharmaceuticals Holding Corp. (TNXP) and Innovus Pharmaceuticals (INNV) Financial Contrast
www.americanbankingnews.com - August 21 at 10:26 AM
nasdaq.com logoTonix Pharmaceuticals to Present Additional Phase 2 Clinical Results and Design of Ongoing Phase 3
www.nasdaq.com - August 21 at 8:44 AM
feeds.benzinga.com logoTonix Pharmaceuticals to Present Additional Phase 2 Clinical Results and Design of Ongoing Phase 3 Trial in Military-Related PTSD at the 2017 Military Health System Research Symposium
feeds.benzinga.com - August 21 at 7:40 AM
americanbankingnews.com logoTonix Pharmaceuticals Holding Corp. (TNXP) CEO Buys $60,000.00 in Stock
www.americanbankingnews.com - August 18 at 4:24 PM
americanbankingnews.com logoTonix Pharmaceuticals Holding Corp. (TNXP) Upgraded to Buy by Roth Capital
www.americanbankingnews.com - August 18 at 9:02 AM
finance.yahoo.com logoTNXP: Patient Enrollment Continues for Phase 3 Study of Tonmya® in PTSD; Interim Analysis Expected in 1H18
finance.yahoo.com - August 18 at 7:58 AM
americanbankingnews.com logoTonix Pharmaceuticals Holding Corp. (TNXP) Releases Earnings Results
www.americanbankingnews.com - August 15 at 10:48 AM
nasdaq.com logoTonix Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Programs Update - Nasdaq
www.nasdaq.com - August 15 at 7:45 AM
finance.yahoo.com logoTonix Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Programs Update
finance.yahoo.com - August 15 at 7:45 AM
prnewswire.com logoToday's Research Report Coverage on Healthcare Stocks -- Perrigo, Immune Pharma, Tonix Pharma, and United Therapeutics
www.prnewswire.com - August 1 at 7:01 AM
americanbankingnews.com logoTonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) to Release Earnings on Monday
www.americanbankingnews.com - July 31 at 8:26 AM
americanbankingnews.com logoAnalyzing Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) and Echo Therapeutics (ECTE)
www.americanbankingnews.com - July 17 at 12:18 AM
americanbankingnews.com logoReviewing Echo Therapeutics (ECTE) & Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP)
www.americanbankingnews.com - July 13 at 8:29 AM
americanbankingnews.com logoEcho Therapeutics (ECTE) vs. Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) Critical Contrast
www.americanbankingnews.com - July 11 at 4:08 PM
streetinsider.com logoTonix Pharma (TNXP) Reports Conditional Acceptance of Tonmya as Proposed Brand Name for TNX-102 SL ... - StreetInsider.com
www.streetinsider.com - July 8 at 2:47 PM
nasdaq.com logoTonix Pharmaceuticals Announces Conditional Acceptance of Tonmya® as Proposed Brand Name for TNX-10
www.nasdaq.com - July 6 at 1:45 PM
finance.yahoo.com logoTonix Pharmaceuticals Announces Conditional Acceptance of Tonmya® as Proposed Brand Name for TNX-102 SL (Cyclobenzaprine HCl Sublingual Tablets) for the Treatment of PTSD
finance.yahoo.com - July 6 at 1:44 PM
americanbankingnews.com logoTonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) versus Echo Therapeutics (ECTE) Head to Head Comparison
www.americanbankingnews.com - July 2 at 8:20 PM
americanbankingnews.com logoTonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) Director Ernest Mario Sells 6,105 Shares
www.americanbankingnews.com - June 30 at 10:30 PM
americanbankingnews.com logoTonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) CEO Seth Lederman Acquires 5,000 Shares
www.americanbankingnews.com - June 30 at 7:28 PM

Social

Chart

Tonix Pharmaceuticals Holding Corp. (TNXP) Chart for Monday, September, 25, 2017

This page was last updated on 9/25/2017 by MarketBeat.com Staff